Sagimet Biosciences INC. 8-K Filing
Ticker: SGMT · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1400118
Sentiment: neutral
Filing Stats: 610 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-12-17 07:05:40
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
- $2.5 million — -front payment to TAPI in the amount of $2.5 million upon execution of a term sheet. Pursuan
- $5.5 million — nufacturing-related milestones of up to $5.5 million. The License Agreement terminates upon
Filing Documents
- tm2533462d1_8k.htm (8-K) — 27KB
- tm2533462d1_ex99-1.htm (EX-99.1) — 23KB
- tm2533462d1_ex99-1img001.jpg (GRAPHIC) — 15KB
- tm2533462d1_ex99-1img002.jpg (GRAPHIC) — 11KB
- 0001104659-25-121819.txt ( ) — 257KB
- sgmt-20251217.xsd (EX-101.SCH) — 3KB
- sgmt-20251217_lab.xml (EX-101.LAB) — 33KB
- sgmt-20251217_pre.xml (EX-101.PRE) — 22KB
- tm2533462d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On December 17, 2025, Sagimet Biosciences Inc. (the "Company") issued a press release announcing its entry into a license agreement with Assia Chemical Industries Ltd., doing business as TAPI Technology & API Services ("TAPI"), a subsidiary of Teva Pharmaceutical Industries Ltd. (the "License Agreement"). Under the License Agreement, TAPI granted the Company a global, exclusive license to certain intellectual property rights covering innovative forms of TAPI's resmetirom active pharmaceutical ingredient ("API") for the Company's technical evaluation and manufacture, and, if elected by the Company following an evaluation period, further development of a fixed-dose combination product containing denifanstat and resmetirom. The Company previously made a non-refundable up-front payment to TAPI in the amount of $2.5 million upon execution of a term sheet. Pursuant to the License Agreement, TAPI may be eligible to receive low single-digit royalties and potential additional manufacturing-related milestones of up to $5.5 million. The License Agreement terminates upon the date certain TAPI know-how ceases to be confidential information or the last of the TAPI patents expires, whichever is later, unless earlier terminated by either party in accordance with the terms of the License Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference .
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated December 17, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: December 17, 2025 By: /s/ David Happel David Happel Chief Executive Officer